Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes
Tóm tắt
Từ khóa
Tài liệu tham khảo
Novello, 2003, Chemotherapy for non-small-cell lung cancer, Oncology, 17, 357
Juretic, 1999, Combined modality therapy of non-small cell lung cancers, Ann Oncol, 10, 93, 10.1023/A:1008385731605
Vokes, 1990, Role of systemic therapy in advanced non-small-cell lung cancer, Am J Med, 89, 777, 10.1016/0002-9343(90)90221-X
2004, Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer, N Engl J Med, 350, 351, 10.1056/NEJMoa031644
Sculier, 1994, Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer, Eur J Cancer, 30A, 1342, 10.1016/0959-8049(94)90184-8
Natale, 1997, Overview of current and future chemotherapeutic agents in non-small cell lung cancer, Semin Oncol, 24, S7
1995, Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials, BMJ, 311, 899, 10.1136/bmj.311.7010.899
Schiller, 2002, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer, N Engl J Med, 346, 92, 10.1056/NEJMoa011954
Kelly, 2001, Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial, J Clin Oncol, 19, 3210, 10.1200/JCO.2001.19.13.3210
Abratt, 1998, Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery, Semin Oncol, 25, 35
Rinaldi, 2000, A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial, Ann Oncol, 11, 1295, 10.1023/A:1008334610955
Sandler, 1999, First-line combination chemotherapy for advanced non-small cell lung cancer: the Eastern Cooperative Oncology Group and Southwest Oncology Group experience, Semin Oncol, 26, 44
Cardenal, 1999, Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer, J Clin Oncol, 17, 12, 10.1200/JCO.1999.17.1.12
Zatloukal, 2003, Gemcitabine plus cisplatin versus gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial, Lung Cancer, 41, 321, 10.1016/S0169-5002(03)00233-2
Rudd, 2002, Phase III randomised comparison of gemcitabine and carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIP) in advanced non-small cell lung cancer (NSCLC), Proc Am Soc Clin Oncol, 21, 292a
Sederholm, 2002, Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a phase III study by the Swedish Lung Cancer Study Group (SLUSG), Proc Am Soc Clin Oncol, 21, 291a
Scagliotti, 2002, Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer, J Clin Oncol, 20, 4285, 10.1200/JCO.2002.02.068
Comella, 1999, Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group, J Clin Oncol, 17, 1526, 10.1200/JCO.1999.17.5.1526
Van Meerbeeck, 2001, A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (NSCLC), Proc Am Soc Clin Oncol, 20, 308a
Chang, 2001, Randomized phase II study of vinorelbine plus cisplatinum versus gemcitabine plus cisplatinum in advanced non-small cell lung cancer: a preliminary result, Proc Am Soc Clin Oncol, 20, 336a
Crino, 1999, Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project, J Clin Oncol, 17, 3522, 10.1200/JCO.1999.17.11.3522
Danson S, Clemons M, Middleton M, et al. A randomised study of gemcitabine with carboplatin (GC) versus mitomycin, vinblastine and cisplatin (MVP) or mitomycin C, ifosfamide and cisplatin (MIC) as first line chemotherapy in advanced non-small cell lung cancer (NSCLC). In: Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncologists, 2001, p. 1285 [Abstract].
Gridelli, 2003, Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol, 21, 3025, 10.1200/JCO.2003.06.099
Grigorescu, 2002, Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial, Lung Cancer, 37, 9, 10.1016/S0169-5002(01)00493-7
Melo, 2002, Results of a randomized phase III trial comparing 4 cisplatin (P)-based regimens in the treatment of locally advanced and metastatic non-small cell lung cancer (NSCLC): mitomycin/vinblastine/cisplatin (MVP) is no longer a therapeutic option, Proc Am Soc Clin Oncol, 21, 302a
Parente, 2000, A randomized phase III study of gemcitabine and carboplatin versus vinorelbine and carboplatinum in advanced non-small cell lung cancer (NSCLC), Lung Cancer, 29, S61, 10.1016/S0169-5002(00)80197-X
Sandler, 2000, Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer, J Clin Oncol, 18, 122, 10.1200/JCO.2000.18.1.122
Thomas, 2002, Randomized phase II study of carboplatin/gemcitabine versus cisplatin/vinorelbine in advanced non-small cell lung cancer (NSCLC). (GFPC 99-01 study), Proc Am Soc Clin Oncol, 21, 336a
Egger M, Davey Smith G, Altman DG, editors. Systematic reviews in health care. Meta-analysis in context. London: British Medical Journal, 2001. [2nd ed. of Systematic Reviews, chapter 11]
Jadad, 1996, Assessing the quality of reports of randomized clinical trials: is blinding necessary?, Control Clin Trials, 17, 1, 10.1016/0197-2456(95)00134-4
Moher, 1999, Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement, Lancet, 354, 1896, 10.1016/S0140-6736(99)04149-5
Parmar, 1998, Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints, Stat Med, 17, 2815, 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
Whitehead, 1991, A general parametric approach to the meta-analysis of randomized clinical trials, Stat Med, 10, 1665, 10.1002/sim.4780101105
Crino, 2002, Gemzar platinum combinations: phase III trials in non-small cell lung cancer, Lung Cancer, 38, S9, 10.1016/S0169-5002(02)00351-3
Crino, 2002, New platinum derivatives in advanced non-small cell lung cancer, Suppl Tumori, 1, S24
Sandler, 1999, First-line combination chemotherapy for advanced non-small cell lung cancer: the Eastern Cooperative Oncology Group and Southwest Oncology Group experience, Semin Oncol, 26, 44
Crino, 1995, Superiority of three-drug combination chemotherapy versus cisplatin-etoposide in advanced non-small cell lung cancer: a randomized trial by the Italian Oncology Group for Clinical Research, Lung Cancer, 12, S125, 10.1016/0169-5002(95)00428-4
Waters, 2002, The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of the National Institute of Clinical Excellence (NICE), Br J Cancer, 87, 481, 10.1038/sj.bjc.6600491
Clegg, 2001, A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small cell lung cancer, Health Technol Assess, 5, 1, 10.3310/hta5320
Deeks, 2001, Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis
DerSimonian, 1986, Meta-analysis in clinical trials, Control Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2
Stewart, 1993, Meta-analysis of the literature or of individual patient data: is there a difference?, Lancet, 341, 418, 10.1016/0140-6736(93)93004-K
Bunn, 2002, Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?, J Clin Oncol, 20, 23
Raftopoulos, 2003, Assessing the role of cisplatin dose and dose intensity in advanced non-small-cell lung cancer: a comprehensive review of randomized trials, Proc Am Soc Clin Oncol, 22, 645a
Lilenbaum, 1998, Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival, Cancer, 82, 116, 10.1002/(SICI)1097-0142(19980101)82:1<116::AID-CNCR14>3.0.CO;2-5
Marino, 1995, Single-agent chemotherapy versus combination chemotherapy in advanced non-small cell lung cancer: a quality and meta-analysis study, Lung Cancer, 13, 1, 10.1016/0169-5002(95)00477-I
Marino, 1995, Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer, Cancer, 76, 593, 10.1002/1097-0142(19950815)76:4<593::AID-CNCR2820760409>3.0.CO;2-N
1998, Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials, Lancet, 352, 257, 10.1016/S0140-6736(98)06341-7
Pritchard, 1996, Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer, Ann Intern Med, 125, 723, 10.7326/0003-4819-125-9-199611010-00003
Sakamoto, 2001, Meta-analysis of adjuvant immunochemotherapy using OK-432 in patients with resected non-small-cell lung cancer, J Immunother, 24, 250, 10.1097/00002371-200105000-00009
Sculier, 2001, The role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literature, Br J Cancer, 84, 1150, 10.1054/bjoc.2001.1742
Souquet, 1995, Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer, Lung Cancer, 12, 147, 10.1016/0169-5002(95)00430-9
1998, Polychemotherapy for early breast cancer: an overview of the randomised trials, Lancet, 352, 930, 10.1016/S0140-6736(98)03301-7
National Institutes of Health Consensus Development Panel. National institutes of health consensus development conference statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst 2001; 93 979–89.
Rosell, 2003, Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer, Oncogene, 22, 3548, 10.1038/sj.onc.1206419